To use a number of methods to control for confounding and selection bias to examine the association between lymphadenectomy and survival in a large cohort of women with endometrial cancer.
OBJECTIVE:
To use a number of methods to control for confounding and selection bias to examine the association between lymphadenectomy and survival in a large cohort of women with endometrial cancer.
METHODS:
A retrospective cohort study using the National Cancer Data Base was performed to identify women with endometrioid adenocarcinoma of the endometrium who underwent hysterectomy with or without lymphadenectomy from 1998 to 2011. Traditional regression analysis, propensity score, and an instrumental variable using regional variation in the rate of lymphadenectomy as an instrument were used to examine the association between lymphadenectomy and survival.
RESULTS: A total of 151,089 women treated at 1,336 hospitals were identified; 99,052 (65.6%) patients underwent lymphadenectomy, whereas 52,037 (34.4%) did not. In a multivariable regression model, lymphadenectomy was associated with a 16% reduction in mortality (hazard ratio [HR] 0.84, 95% confidence interval [CI] 0.81-0.87). The results were similar after adjustment for adjuvant therapy (HR 0.85, 95% CI 0.82-0.87). The results were largely unchanged and suggested that lymphadenectomy was associated with improved survival after application of a propensity score analysis. In contrast, in the instrumental variable analysis, there was not a statistically significant association between lymphadenectomy and survival (HR 0.75, 95% CI 0.53-1.06), even after adjustment for adjuvant treatment (HR 0.76, 95% CI 0.54-1.06). The results were unchanged for women with T1A and T1B tumors.
CONCLUSION:
Lymphadenectomy is associated with a modest, if any, effect on survival for women with endometrial cancer. T he treatment of endometrial cancer has evolved over the past three decades. In the 1980s, the disease was predominantly treated with intracavitary radiation followed by hysterectomy. With the greater understanding of the patterns of spread, treatment shifted to primary surgery with lymph node sampling in higher risk patients. Nodal status is used to tailor adjuvant therapy; women with nodal disease were treated with pelvic radiation, whereas those with negative nodes received brachytherapy or observation. 1, 2 Data from observational studies emerged suggesting a therapeutic benefit for lymphadenectomy, even in women without nodal metastasis, and nodal evaluation became more widespread and shifted from sampling to a full lymphadenectomy of the pelvic and paraaortic nodes. [3] [4] [5] [6] [7] [8] [9] [10] The benefits of lymph node dissection for endometrial cancer were challenged by the publication of two randomized trials. 11, 12 These European trials both reported no association between lymphadenectomy and survival. 11, 12 However, concern has been raised that these trials were underpowered to detect a benefit for lymphadenectomy, that the quality of lymphadenectomy dissection performed was suboptimal, and the ability of the status of the nodes to guide therapy unclear. 1, 13, 14 In the United States, lymphadenectomy remains a component of therapy for many women with endometrial cancer. An important limitation of observational studies is the inability to control for confounding factors that influence outcome. [15] [16] [17] A variety of statistical techniques are now available to help overcome this limitation. Propensity score analysis estimates the probability of treatment, the propensity score, and then uses this score to assess outcomes while controlling for measured confounders. 15 An instrumental variable analysis is a technique that leverages variation in treatment, referred to as an instrument, to control for both measured and unmeasured confounding factors. 15, 16 Given the conflicting data surrounding the benefits of lymph node dissection for endometrial cancer, we performed a population-based analysis to examine the association between lymphadenectomy and survival. We analyzed a large cohort of women using a variety of statistical methodologies to control for measured and unmeasured confounders.
MATERIALS AND METHODS
A retrospective cohort study using the National Cancer Data Base was performed. 18, 19 Data on incident cancer cases from more than 1,500 Commission on Cancer-affiliated hospitals encompassing approximately 70% of all newly diagnosed cancers are captured in the data set. Data on patient demographics, clinical data, tumor characteristics, staging, treatment, and overall survival are collected. 18, 19 The database contains deidentified data and was deemed exempt by the Columbia University institutional review board.
Women with endometrioid adenocarcinoma of the endometrium diagnosed from 1998 to 2011 who underwent hysterectomy were selected. Patients who received preoperative radiation and those who had another primary tumor before the diagnosis of uterine cancer were excluded. Because the study spanned the timeframe including the American Joint Commission on Cancer staging systems 5-7, we converted the T stage of all patients to uniform nomenclature and included the following T stages: T1A (tumor limited to the endometrium or less than 50% of the myometrium), T1B (tumor with greater than 50% myometrial invasion), or T2 (cervical stromal involvement). Because the goal of the analysis was to explore the influence of lymphadenectomy on outcome, we included women regardless of their nodal status (positive lymph nodes, negative lymph nodes, lymph nodes unknown). Women with primary tumor spread beyond the uterus (greater than T2) or metastatic disease were excluded.
Lymph node dissection was considered the removal of any lymph nodes. We performed sensitivity analyses in which the extent of lymphadenectomy was assessed. In these analyses, the cohort was stratified as those women who had less than 10 lymph nodes removed and those who had 10 or more nodes removed (extensive lymphadenectomy).
Clinical variables analyzed included age (younger than 40, 40-49, 50-59, 60-6, 70 years or older), race (white, black, other), insurance (commercial, Medicare, Medicaid, uninsured, other), region of residence, and area level education (percentage of residents who did not complete high school: less than 14%, 14-19.9%, 20-28.9%, 29% or greater). Tumor grade was classified as well, moderately, or poorly differentiated. Use of adjuvant radiotherapy was grouped as: none, brachytherapy, and external beam radiation (with or without brachytherapy). Use of chemotherapy during the first course of treatment was recorded.
Hospital location was classified as metropolitan, urban, or rural and hospitals are also classified as academic-research cancer centers or community cancer centers. 19 Annualized hospital volume was recorded as the mean annual number of cases cared for in years in which a given hospital recorded at least one patient and included as a continuous variable in all analyses.
Frequency distributions between groups were compared using a standardized difference with a value of 0.10 or less considered to indicate good balance. 20 Multivariable generalized estimating equations with a Poisson distribution and log link function were developed to examine predictors of lymphadenectomy while controlling for other clinical, demographic, and hospital characteristics.
The association between performance of lymphadenectomy and overall survival was assessed using multivariable Cox proportional hazards analysis through use of a propensity score (matching, inverse probability of treatment weights, and stratification or deciles) and an instrumental variable analysis. For each methodology, we developed a model that included only lymphadenectomy, a clinical model that included lymphadenectomy and all patient (clinical and tumor) and hospital characteristics, and a clinical and treatment model that included all of the variables in the clinical model as well as adjuvant therapy (chemotherapy and radiation) administered.
The propensity score is the predicted probability of treatment. 15, 16, 21 To calculate the propensity score, we fit a logistic regression model that included all of the clinical, oncologic, and hospital characteristics and two-way interaction terms (only those interaction terms with a P value of ,.05 for stage T1B and T2 to allow model convergence) to determine the probability of undergoing lymphadenectomy. The predicted probability (the propensity score) was estimated for each patient and ranged from 0 to 1.
The propensity score matching relied on a Greedy 5:1 digit matching algorithm. Women who underwent lymphadenectomy were matched to women in a control group to five digits of the propensity score. For those participants for whom a match was not identified, a four-digit match was applied. This process was continued down to a one-digit match for those who remained unmatched (Appendix 1, available online at http://links.lww.com/AOG/A732). We also applied an inverse probability of treatment weighting approach for propensity score analysis. 16, 22 Using an inverse probability of treatment weighting approach, each patient was assigned a differential weight based on their calculated propensity score. Using this approach allows inclusion of all participants and does not require a match. The weighting assumptions of the inverse probability of treatment weighting approach assigned patients who underwent a lymphadenectomy a weight of 1/propensity score and those who did not undergo a lymphadenectomy a weight of 1/(1-propensity score). 16, 22 Marginal Cox proportional hazards regression models were used as the final model for propensity score analysis to estimate the hazard ratio for mortality with receipt of lymphadenectomy accounting for hospital clustering.
An instrumental variable analysis is an analytic methodology that attempts to adjust for measured and unmeasured confounders through application of an exogenous instrument. 15, 16, 23 The instrument, or instrumental variable, is a characteristic associated with treatment but not outcome. Variation in the instrument approximates randomization and results in groups of patients with similar characteristics, including unmeasured factors. 16 The instrumental variable for our analysis was geographic variation in performance of lymphadenectomy. Within the data set, hospitals are classified into nine unique geographic regions. We calculated the predicted probability of performance of lymphadenectomy for each patient while controlling for all of the clinical, demographic, and hospital characteristics. Within each region, we then calculated the difference between the observed and expected rates of lymphadenectomy. The difference in the observed-toexpected rate served as the instrumental variable. Regions with a positive value of the instrumental variable had more patients who underwent lymphadenectomy than predicted, whereas regions with a negative value for the instrumental variable had fewer patients that predicted undergo lymphadenectomy. We used the 1-year lagged rate of lymphadenectomy (performance of lymphadenectomy in the regions in the year prior) to allow greater independence from current patients' medical conditions as previously described. 16 A sensitivity analysis using the current year rate of lymphadenectomy was also performed.
The primary instrumental variable analysis relied on the two-stage residual inclusion methodology. 16, 24 In the first stage, a logistic regression model was used to generate the residual (difference between observed and predicted probability of lymphadenectomy). We noted that the lagged lymphadenectomy had a statistically significant effect on patients' receipt of lymphadenectomy, and there was substantial geographic variation (F5758.08) (P,.001). The residual obtained from the first stage was then included in the second stage of a marginal Cox proportional hazards regression model to estimate the hazard ratio for mortality with performance of lymphadenectomy. We performed further sensitivity analyses for the instrumental variable analysis using the two-stage predictor substitution methodology to explore the effects of model specification on the estimates of the treatment effect. [25] [26] [27] The effect of lymphadenectomy on survival outcome was also estimated in absolute scale (survival difference and standard error) through adjusted survival curves in clinical and adjuvant treatment adjusted models for traditional regression, propensity score analysis, and instrumental variable analysis. 28, 29 All analyses were performed with SAS 9.3. All statistical tests were two-sided. A P value of ,.05 was considered statistically significant.
RESULTS
A total of 151,089 women treated at 1,336 hospitals were identified. Within the cohort, 99,052 (65.6%) patients underwent lymphadenectomy, whereas 52,037 (34.4%) did not have lymph node sampling ( Table 1 ). The rate of lymphadenectomy increased over time, from 51.8% in 1998 to a peak of 70.6% in 2007, and then declined slightly through 2011 (Fig. 1) . The overall rate of lymphadenectomy was 60.7% for T1A tumors, 78.7% for T1B tumors, and 77.9% for T2 tumors. Within the cohort, the median follow-up time was 54.5 months in women who underwent lymphadenectomy and 60.9 months in those women who did not (Appendix 2, available online at http://links.lww.com/AOG/A732).
In the unadjusted analysis, there were significant differences in the clinical and demographic Unauthorized reproduction of this article is prohibited.
characteristics of patients who underwent lymphadenectomy (Table 1) . In a multivariable model, more recent year of diagnosis, nonwhite, nonblack race, older age, commercial insurance, residence outside of New England, higher area-level education, higher tumor grade and T stage, and treatment at an academic center were all associated with performance of lymphadenectomy (Appendix 3, available online at http://links.lww.com/AOG/A732). After calculation of the propensity score and matching or application of an inverse probability of treatment weighting algorithm, the patient and hospital characteristics were well balanced across the cohorts (Table 1 ; Appendix 4 [Appendix 4 is available online at http://links.lww.com/AOG/ A732]). The primary instrument, the regional rate SD, standardized difference. Data are n (%) or median (interquartile range) unless otherwise specified. * Frequency numbers are rounded to integers based on weight. The conventional SD for weighted cohort is consistent with the analysis in weighted regression model using SURVEYLOGISTIC procedure. † Four thousand three hundred twenty-five patients treated in 1998 excluded because data from 1997 to calculate the previous year lymphadenectomy rate were unavailable. ‡ SD5difference in means or proportions divided by standard error. SD#0.10 is considered to indicate good balance between groups. Unauthorized reproduction of this article is prohibited. CI, confidence interval; IPTW, inverse probability of treatment weighting. Data are adjusted survival probability in % (95% confidence interval) unless otherwise specified. Multivariable Cox proportional hazard regression model adjusted for clinical characteristics and adjuvant treatment. * Survival difference5adjusted survival probability of no lymph node dissection-adjusted survival probability of lymph node dissection. † Statistically significant survival difference (P,.05).
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of lymphadenectomy, varied from 56.0% to 61.0% in the lowest quintile region to 70.7% in the highest quintile region (Appendix 5, available online at http://links.lww.com/AOG/A732). When the cohort was divided at the median value of the instrument (the lagged difference between observed and predicted lymphadenectomy rate), there was a 7.2% difference in the instrument's value between the two groups ( Table 1) . Patients in the group below the median instrumental variable value were 3.6% less likely to undergo lymphadenectomy, whereas those above the median were, on average, 3.6% more likely to undergo lymphadenectomy. Grouping patients by the instrument resulted in a similar distribution of the characteristics in the two groups except for facility type.
In a regression model adjusted for clinical characteristics, performance of lymphadenectomy was associated with a 16% reduction in mortality (hazard ratio [HR] 0.84, 95% confidence interval [CI] 0.81-0.87) ( Table 2) . The results were similar after adjustment for clinical characteristics and adjuvant therapy (HR 0.85, 95% CI 0.82-0.87). The results were largely unchanged and suggested that lymphadenectomy was associated with improved survival after application of propensity score stratification, matching, or inverse probability treatment weighting. In contrast, in the instrumental variable analysis, there was not a statistically significant association between lymphadenectomy and survival (HR 0.75, 95% CI 0.53-1.06); the results were similar after adjustment for adjuvant treatment (HR 0.76, 95% CI 0.54-1.06).
When stratified by T stage, the results for T1A and T1B tumors were similar; the multivariable survival models and propensity score models all suggested reduced mortality with lymphadenectomy. However, the lagged instrumental variable analysis found no statistically significant association between lymphadenectomy and survival. In contrast, for women with T2 tumors, all of the analytic methodologies noted reduced mortality in women who underwent lymphadenectomy (Table 2 ). Among women with T1A tumors, 5-year survival was 93.2% (95% CI 93.0-93.4%) in women who underwent lymphadenectomy compared with 92.4% (95% CI 92.2-92.7%) in those without lymphadenectomy (Table 3 ). For those with T1B tumors, 5-year survival was 82.4% (95% CI 81.8-83.0%) after lymphadenectomy compared with 78.4% (95% CI 77.4-79.5%) without lymphadenectomy.
We performed a series of sensitivity analyses to estimate the robustness of our findings. When the same year rate of lymphadenectomy (as opposed to lagged lymphadenectomy rate) was assessed as the instrument, the results were similar except that the findings for T2 tumors were attenuated somewhat (Appendix 6, available online at http://links.lww.com/AOG/A732). When the analytic methodology used to calculate the instrumental variable was altered through use of a twostage predictor substitution, the results were very 3-10 A report of more than 12,000 women noted improved survival in women with deep myometrial invasion or high-grade, superficially invasive endometrial cancer who underwent lymphadenectomy. 3 In our cohort, we also noted improved survival in the observational analysis for all substages and the magnitude of the findings was largely unchanged even after application of propensity score matching. In contrast, the instrumental variable analysis found no association between lymphadenectomy and survival for either T1A or T1B tumors.
Our data are in accord with two prior randomized trials that both demonstrated no association between lymphadenectomy and survival. 11, 12 A trial of more than 1,400 women from the United Kingdom found no difference in survival with lymphadenectomy for apparent uterine-confined disease. 11 An Italian trial of 514 patients reported similar findings. 12 Despite the consistent findings of these trials, methodologic concerns, including the quality of lymphadenectomy (low number of nodes, lack of paraaortic nodes removed), enrollment of few patients with positive nodes as well as concerns regarding the power of the studies to detect differences in survival have led to continued controversy about the utility of lymphadenectomy. 1, 13, 14 The goal of an instrumental variable analysis is to provide pseudorandomization to help control for unmeasured confounding. 16, 30 The results of our instrumental variable analysis are in line with the randomized data for lymphadenectomy and also suggest a minimal association between the procedure on survival. Furthermore, given the large sample size included, we could specifically analyze higher risk women and yet we still found no association between lymphadenectomy and survival. Finally, to address concerns regarding the quality of the lymphadenectomy performed, we performed sensitivity analyses limiting the cohort to removal of 10 or more nodes and still noted no association with survival.
Even if lymphadenectomy is not directly associated with survival, the procedure provides data to tailor adjuvant therapy, potentially avoiding treatment in lower risk patients. One report noted that when matched by grade and stage, women with high-risk disease who underwent lymphadenectomy were less likely to receive adjuvant whole pelvic radiotherapy. 31 However, the lack of standardized adjuvant therapy recommendations for endometrial cancer further complicates the interpretation of trials of lymphadenectomy. Women with nodal metastases are now commonly treated with chemotherapy, often in combination with radiation. 32 However, women with early-stage disease with high-risk features are increasingly also receiving chemotherapy, thus potentially negating some of the benefit of lymphadenectomy. 33 We recognize a number of limitations. Although an instrumental variable analysis compensates for unmeasured confounders, the methodology is sensitive to a number of underlying assumptions. First, the instrument should be associated with variation in treatment. An F statistic of greater than 10 has been used as a surrogate to fulfill this assumption. In our analysis, the F statistic for the lagged lymphadenectomy rate was 758. Second, and more difficult to assess statistically, the instrument should not be directly associated with the outcome. 34 Although this assumption is difficult to verify, geographic variation has been widely used as an instrumental variable. 15, 16, 30, 34 Third, the data set does not capture complete data on some factors that may have affected decision-making, including lymphovascular space invasion, intraoperative findings, and comorbidity. Similarly, using administrative data, it is impossible to distinguish patients with grossly enlarged nodes who underwent resection compared with diagnostic sampling. In our analysis, by definition, these women were included in the lymphadenectomy cohort. Lastly, there is no standard definition for what constitutes an adequate lymphadenectomy. We performed a wide range of sensitivity analyses examining removal of different numbers of lymph nodes.
For gynecologists, these data highlight the difficulty in the decision to perform lymphadenectomy. In a recent decision analysis for clinical stage I tumors, 3-year survival rates ranged from 88% to 93% across various scenarios, suggesting that outcomes are good regardless of the therapeutic approach chosen. 1, 13 Similarly, our data suggest that at the population level, any survival benefit from lymphadenectomy is likely very small. Whether the small potential benefit of lymphadenectomy justifies the costs and potential complications of the procedure and whether further prospective study is warranted or even feasible remains a question of active debate. 1 
